CoChat
Sign Up
Cited by 69Amyotrophic Lateral Sclerosis ResearchMicroRNA in disease regulationMuscle Physiology and Disorders

Aberration of miRNAs expression in leukocytes from sporadic amyotrophic lateral sclerosis

Open access
Chen, YongPing, Wei, QianQian, Chen, XuePing, Li, ChunYu, Cao, Bei, Ou, RuWei, Hadano, Shinji, Shang, Hui-Fang·2016·Frontiers in Molecular Neuroscience
DOI 10.3389/fnmol.2016.00069PMC PMC4987348
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Accumulating evidence indicates that miRNAs play an important role in the development of amyotrophic lateral sclerosis (ALS). Most of previous studies on miRNA dysregulation in ALS focused on the alterative expression in ALS animal model or in limited samples from European patients with ALS. In the present study, the miRNA expression profiles were investigated in Chinese ALS patients to explore leukocytes miRNAs as a potential biomarker for the diagnosis of ALS. METHODS: We analyzed the expression profiles of 1733 human mature miRNAs using microarray technology in leukocytes obtained from 5 patients with sporadic ALS (SALS) and 5 healthy controls. An independent group of 83 SALS patients, 24 Parkinson's disease (PD) patients and 61 controls was used for validation by real-time polymerase chain reaction assay. Area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy. In addition, target genes and signaling information of validated differential expression miRNAs were predicted using Bioinformatics. RESULTS: Eleven miRNAs, including four over-expressed and seven under-expressed miRNAs detected in SALS patients compared to healthy controls were selected for validation. Four under-expressed microRNAs, including hsa-miR-183, hsa-miR-193b, hsa-miR-451, and hsa-miR-3935, were confirmed in validation stage by comparison of 83 SALS patients and 61 HCs. Moreover, we identified a miRNA panel (hsa-miR-183, hsa-miR-193b, hsa-miR-451, and hsa-miR-3935) having a high diagnostic accuracy of SALS (AUC 0.857 for the validation group). However, only hsa-miR-183 was significantly lower in SALS patients than that in PD patients and in HCs, while no differences were found between PD patients and HCs. By bioinformatics analysis, we obtained a large number of target genes and signaling information that are linked to neurodegeneration. CONCLUSION: This study provided evidence of abnormal miRNA expression patterns in the peripheral blood leukocytes of SALS patients. Leukocytes miRNAs provide a promising opportunity for detection of SALS. The specificity of under-expression of hsa-miR-183 in SALS needs to be confirmed by further miRNA studies on other neurodegenerative diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnmol.2016.00069

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-193b-3p is downregulated in ALS patients.

    “In this study, we tried to clarify whether miR-193b-3p, a downregulated miRNA in ALS patients reported in our previous study (Chen et al., 2016), involves in cell survival by targeting TSC1/mTOR signaling in autophagy (Figure 6).”

    From Downregulation of MicroRNA-193b-3p Promotes Autophagy and Cell Survival by Targeting TSC1/mTOR Signaling in NSC-34 Cells (2017) · cites this paper as Chen et al., 2016

    The Discussion reports lower hsa-miR-193b expression in leukocytes from Chinese patients with sporadic ALS than in healthy controls. Our copy does not identify the measured miRNA as the specific 3p form, so it supports the downregulation finding but not that added specificity. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • miR-193b-3p was downregulated in sporadic ALS patients and provided high diagnostic accuracy for sporadic ALS.

    “We noted that miR-193b-3p was downregulated in sALS patients and provided high diagnostic accuracy for sALS (Chen et al., 2016).”

    From Downregulation of MicroRNA-193b-3p Promotes Autophagy and Cell Survival by Targeting TSC1/mTOR Signaling in NSC-34 Cells (2017) · cites this paper as Chen et al., 2016

    The Discussion reports that hsa-miR-193b was downregulated in sporadic ALS patients relative to healthy controls. But the paper does not identify the measured form as miR-193b-3p, and its reported AUCs for miR-193b (0.713 in the Results and 0.62 in the Discussion) do not support describing its individual diagnostic accuracy as high. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 67 · Cited by 69

Research works printed but not linked: 62

  1. Alural B. Duran G. A. Tufekci K. U. Allmer J. Onkal Z. Tunali D.. (2014). EPO Mediates Neurotrophic, Neuroprotective, Anti-Oxidant, and Anti-Apoptotic Effects via Downregulation of miR-451 and miR-885-5p in SH-SY5Y Neuron-Like Cells. Front. Immunol. 5: 475. 10.3389/fimmu.2014.00475 25324845 PMC4179732 · DOI
  2. Andersen P. M. Abrahams S. Borasio G. D. de Carvalho M. Chio A. Van Damme P.. (2012). EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. Eur. J. Neurol. 19, 360– 375. 10.1111/j.1468-1331.2011.03501.x 21914052 · DOI · Paper page
  3. Bartel D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215– 233. 10.1016/j.cell.2009.01.002 19167326 PMC3794896 · DOI · Paper page
  4. Bolognani F. Perrone-Bizzozero N. I. (2008). RNA-protein interactions and control of mRNA stability in neurons. J. Neurosci. Res. 86, 481– 489. 10.1002/jnr.21473 17853436 · DOI
  5. Borovecki F. Lovrecic L. Zhou J. Jeong H. Then F. Rosas H. D.. (2005). Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 102, 11023– 11028. 10.1073/pnas.0504921102 16043692 PMC1182457 · DOI
  6. Brooks B. R. Miller R. G. Swash M. Munsat T. L. (2000). El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 293– 299. 10.1080/146608200300079536 11464847 · DOI · Paper page
  7. Campos-Melo D. Droppelmann C. A. He Z. Volkening K. Strong M. J. (2013). Altered microRNA expression profile in Amyotrophic Lateral Sclerosis: a role in the regulation of NFL mRNA levels. Mol. Brain 6: 26. 10.1186/1756-6606-6-26 23705811 PMC3668997 · DOI
  8. Cao L.-L. Xie J.-W. Lin Y. Zheng C.-H. Li P. Wang J.-B.. (2014). miR-183 inhibits invasion of gastric cancer by targeting Ezrin. Int. J. Clin. Exp. Pathol. 7, 5582– 5594. 25337200 PMC4203171
  9. Cellura E. Spataro R. Taiello A. C. La Bella V. (2012). Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin. Neurol. Neurosurg. 114, 550– 554. 10.1016/j.clineuro.2011.11.026 22169158 · DOI
  10. Chen J. Feilotter H. E. Pare G. C. Zhang X. Pemberton J. G. Garady C.. (2010). MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol. 176, 2520– 2529. 10.2353/ajpath.2010.091061 20304954 PMC2861116 · DOI
  11. Chen X. Feng W. Huang R. Guo X. Chen Y. Zheng Z.. (2014). Evidence for peripheral immune activation in amyotrophic lateral sclerosis. J. Neurol. Sci. 347, 90– 95. 10.1016/j.jns.2014.09.025 25312013 · DOI
  12. Cheng L. Doecke J. D. Sharples R. A. Villemagne V. L. Fowler C. J. Rembach A.. (2014). Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. Mol. Psychiatry 20, 1188– 1196. 10.1038/mp.2014.127 25349172 · DOI · Paper page
  13. Cloutier F. Marrero A. O'Connell C. Morin P. Jr. (2015). MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis. J. Mol. Neurosci. 56, 102– 112. 10.1007/s12031-014-0471-8 25433762 · DOI
  14. De Felice B. Guida M. Coppola C. De Mieri G. Cotrufo R. (2012). A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 508, 35– 40. 10.1016/j.gene.2012.07.058 22903028 · DOI
  15. Droppelmann C. A. Campos-Melo D. Ishtiaq M. Volkening K. Strong M. J. (2014). RNA metabolism in ALS: when normal processes become pathological. Amyotroph. Lateral Scler. Frontotemporal. Degener. 15, 321– 336. 10.3109/21678421.2014.881377 24555412 · DOI
  16. Drusco A. Bottoni A. Laganà A. Acunzo M. Fassan M. Cascione L.. (2015). A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget 6, 20829– 20839. 10.18632/oncotarget.4096 26246487 PMC4673232 · DOI
  17. Du J. Liu S. He J. Liu X. Qu Y. Yan W.. (2015). MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Oncotarget 6, 14993– 15007. 10.18632/oncotarget.3802 25915427 PMC4558131 · DOI
  18. Freischmidt A. Müller K. Ludolph A. C. Weishaupt J. H. (2013). Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 1: 42. 10.1186/2051-5960-1-42 24252274 PMC3893596 · DOI
  19. Freischmidt A. Müller K. Zondler L. Weydt P. Mayer B. von Arnim C. A.. (2015). Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 36, 2660.e15– 2660.e20. 10.1016/j.neurobiolaging.2015.06.003 26142125 · DOI
  20. Friedman R. C. Farh K. K. Burge C. B. Bartel D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92– 105. 10.1101/gr.082701.108 18955434 PMC2612969 · DOI · Paper page
  21. Gao X. N. Lin J. Gao L. Li Y. H. Wang L. L. Yu L. (2011). MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk. Res. 35, 1226– 1232. 10.1016/j.leukres.2011.06.010 21724256 · DOI
  22. Gao X. Xu Z. (2008). Mechanisms of action of angiogenin. Acta Biochim. Biophys. Sin. 40, 619– 624. 10.1111/j.1745-7270.2008.00442.x 18604453 · DOI
  23. Hansen T. Olsen L. Lindow M. Jakobsen K. D. Ullum H. Jonsson E.. (2007). Brain expressed microRNAs implicated in schizophrenia etiology. PLoS ONE 2: e873. 10.1371/journal.pone.0000873 17849003 PMC1964806 · DOI
  24. Hastings M. L. Palma J. Duelli D. M. (2012). Sensitive PCR-based quantitation of cell-free circulating microRNAs. Methods 58, 144– 150. 10.1016/j.ymeth.2012.07.026 22884953 PMC3508311 · DOI
  25. Hu H. Li S. Liu J. Ni B. (2012). MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells. Acta Biochim. Biophys. Sin. 44, 424– 430. 10.1093/abbs/gms018 22491710 · DOI
  26. Hughes A. J. Daniel S. E. Kilford L. Lees A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatr. 55, 181– 184. 10.1136/jnnp.55.3.181 1564476 PMC1014720 · DOI · Paper page
  27. Ishtiaq M. Campos-Melo D. Volkening K. Strong M. J. (2014). Analysis of novel NEFL mRNA targeting microRNAs in amyotrophic lateral sclerosis. PLoS ONE 9: e85653. 10.1371/journal.pone.0085653 24454911 PMC3893244 · DOI
  28. Jeyaseelan K. Lim K. Y. Armugam A. (2008). MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke 39, 959– 966. 10.1161/STROKEAHA.107.500736 18258830 · DOI
  29. Kimura F. Fujimura C. Ishida S. Nakajima H. Furutama D. Uehara H.. (2006). Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66, 265– 267. 10.1212/01.wnl.0000194316.91908.8a 16434671 · DOI
  30. Koval E. D. Shaner C. Zhang P. du Maine X. Fischer K. Tay J.. (2013). Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum. Mol. Genet. 22, 4127– 4135. 10.1093/hmg/ddt261 23740943 PMC3781640 · DOI · Paper page
  31. Kwiatkowski T. J. Jr. Bosco D. A. Leclerc A. L. Tamrazian E. Vanderburg C. R. Russ C. Jr.. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205– 1208. 10.1126/science.1166066 19251627 · DOI
  32. Kye M. J. Niederst E. D. Wertz M. H. Goncalves Ido C. Akten B. Dover K. Z.. (2014). SMN regulates axonal local translation via miR-183/mTOR pathway. Hum. Mol. Genet. 23, 6318– 6331. 10.1093/hmg/ddu350 25055867 PMC4271102 · DOI
  33. Lenarduzzi M. Hui A. B. Alajez N. M. Shi W. Williams J. Yue S.. (2013). MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. PLoS ONE 8: e53765. 10.1371/journal.pone.0053765 23335975 PMC3546079 · DOI
  34. Li X. F. Yan P. J. Shao Z. M. (2009). Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 28, 3937– 3948. 10.1038/onc.2009.245 19701247 · DOI
  35. Ling S. Ruiqin M. Guohong Z. Ying W. (2015). Expression and prognostic significance of microRNA-451 in human epithelial ovarian cancer. Eur. J. Gynaecol. Oncol. 36, 463– 468. 26390704
  36. Liu C. G. Song J. Zhang Y. Q. Wang P. C. (2014). MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease. Mol. Med. Rep. 10, 2395– 2400. 10.3892/mmr.2014.2484 25119742 · DOI
  37. Lowery A. J. Miller N. Dwyer R. M. Kerin M. J. (2010). Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer 10: 502. 10.1186/1471-2407-10-502 20858276 PMC2955037 · DOI
  38. Lu Y. Y. Zheng J. Y. Liu J. Huang C. L. Zhang W. Zeng Y. (2015). miR-183 induces cell proliferation, migration, and invasion by regulating PDCD4 expression in the SW1990 pancreatic cancer cell line. Biomed. Pharmacother. 70, 151– 157. 10.1016/j.biopha.2015.01.016 25776494 · DOI
  39. Marcuzzo S. Kapetis D. Mantegazza R. Baggi F. Bonanno S. Barzago C.. (2014). Altered miRNA expression is associated with neuronal fate in G93A-SOD1 ependymal stem progenitor cells. Exp. Neurol. 253, 91– 101. 10.1016/j.expneurol.2013.12.007 24365539 · DOI
  40. Martínez H. R. Molina-López J. F. Cantú-Martínez L. González-Garza M. T. Moreno-Cuevas J. E. Couret-Alcaraz P.. (2011). Survival and clinical features in Hispanic amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. 12, 199– 205. 10.3109/17482968.2010.550302 21344998 · DOI
  41. Minones-Moyano E. Porta S. Escaramis G. Rabionet R. Iraola S. Kagerbauer B.. (2011). MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet. 20, 3067– 3078. 10.1093/hmg/ddr210 21558425 · DOI
  42. Nolan K. Mitchem M. R. Jimenez-Mateos E. M. Henshall D. C. Concannon C. G. Prehn J. H. M. (2014). Increased Expression of MicroRNA-29a in ALS Mice: functional analysis of its inhibition. J. Mol. Neurosci. 53, 231– 241. 10.1007/s12031-014-0290-y 24696165 · DOI
  43. Paganoni S. Macklin E. A. Lee A. Murphy A. Chang J. Zipf A.. (2014). Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 453– 456. 10.3109/21678421.2014.903974 24981792 PMC4433003 · DOI
  44. Parisi C. Arisi I. D'Ambrosi N. Storti A. E. Brandi R. D'Onofrio M.. (2013). Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis. 4, e959. 10.1038/cddis.2013.491 24336079 PMC3877562 · DOI
  45. Renton A. E. Chiò A. Traynor B. J. (2014). State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17– 23. 10.1038/nn.3584 24369373 PMC4544832 · DOI
  46. Rowland L. P. Shneider N. A. (2001). Amyotrophic lateral sclerosis. N. Engl. J. Med. 344, 1688– 1700. 10.1056/NEJM200105313442207 11386269 · DOI
  47. Russell A. P. Wada S. Vergani L. Hock M. B. Lamon S. Léger B.. (2012). Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol. Dis. 49, 107– 117. 10.1016/j.nbd.2012.08.015 22975021 · DOI
  48. Sanchez-Ortiz E. Cho W. Nazarenko I. Mo W. Chen J. Parada L. F. (2014). NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development. Genes Dev. 28, 2407– 2420. 10.1101/gad.246603.114 25367036 PMC4215185 · DOI
  49. Seo J. Bakay M. Chen Y. W. Hilmer S. Shneiderman B. Hoffman E. P. (2004). Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. Bioinformatics 20, 2534– 2544. 10.1093/bioinformatics/bth280 15117752 · DOI
  50. Serafin A. Foco L. Zanigni S. Blankenburg H. Picard A. Zanon A.. (2015). Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD. Neurology 84, 645– 653. 10.1212/WNL.0000000000001258 25596505 · DOI
  51. Sethi P. Lukiw W. J. (2009). Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci. Lett. 459, 100– 104. 10.1016/j.neulet.2009.04.052 19406203 · DOI · Paper page
  52. Shinde S. Arora N. Bhadra U. (2013). A complex network of MicroRNAs expressed in brain and genes associated with amyotrophic lateral sclerosis. Int. J. Genomics 2013: 383024. 10.1155/2013/383024 23936767 PMC3723150 · DOI
  53. Shioya M. Obayashi S. Tabunoki H. Arima K. Saito Y. Ishida T.. (2010). Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol. Appl. Neurobiol. 36, 320– 330. 10.1111/j.1365-2990.2010.01076.x 20202123 · DOI
  54. Strong M. J. (2010). The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. 288, 1– 12. 10.1016/j.jns.2009.09.029 19840884 · DOI
  55. Strong M. J. Volkening K. Hammond R. Yang W. Strong W. Leystra-Lantz C.. (2007). TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol. Cell. Neurosci. 35, 320– 327. 10.1016/j.mcn.2007.03.007 17481916 · DOI
  56. Toivonen J. M. Manzano R. Oliván S. Zaragoza P. Garcia-Redondo A. Osta R. (2014). MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS ONE 9: e89065. 10.1371/journal.pone.0089065 24586506 PMC3930686 · DOI
  57. Weeraratne S. D. Amani V. Teider N. Pierre-Francois J. Winter D. Kye M. J.. (2012). Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 123, 539– 552. 10.1007/s00401-012-0969-5 22402744 PMC6172007 · DOI
  58. Williams A. H. Valdez G. Moresi V. Qi X. McAnally J. Elliott J. L.. (2009). MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326, 1549– 1554. 10.1126/science.1181046 20007902 PMC2796560 · DOI
  59. Yang R. Huang R. Chen D. Song W. Zeng Y. Zhao B.. (2011). Causes and places of death of patients with amyotrophic lateral sclerosis in south-west China. Amyotroph. Lateral Scler. 12, 206– 209. 10.3109/17482968.2011.572979 21506897 · DOI
  60. Yuan D. Li K. Zhu K. Yan R. Dang C. (2015). Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol. Ther. 16, 268– 275. 10.1080/15384047.2014.1002327 25629978 PMC4622949 · DOI
  61. Zeng T. Peng L. Chao C. Fu B. Wang G. Wang Y.. (2014). miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT. Int. J. Clin. Exp. Pathol. 7, 7653– 7662. 25550801 PMC4270518
  62. Zhu J. Feng Y. Ke Z. Yang Z. Zhou J. Huang X.. (2012). Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am. J. Pathol. 180, 2440– 2451. 10.1016/j.ajpath.2012.02.023 22525461 · DOI

Authors
Chen, Y., Wei, Q., Chen, X., Li, C., Cao, B., Ou, R., Hadano, S., & Shang, H.-F.
Affiliations
  • Sichuan University (CN)
  • Tokai University (JP)
ORCID
Venue
Frontiers in Molecular Neuroscience
Publisher
Frontiers Media SA
Published
2016-08-17
Volume
9
Pages
69-69
ISSN
1662-5099 (ISSN-L)
DOI
10.3389/fnmol.2016.00069
PMC
PMC4987348
OpenAlex
W2510868781
Cited by
69
References
67
Citations by year
2026: 1 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 6 · 2019: 6 · 2018: 12 · 2017: 3
FWCI
5.26
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Molecular Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Japan Society for the Promotion of Science (26290018)
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
Keywords
amyotrophic lateral sclerosis, sporadic ALS, microRNA expression, leukocytes, peripheral blood biomarkers, miRNA panel, Parkinson's disease, neurodegeneration, differential gene expression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review